2007: Pharmaco-Economics of Treatments for Rheumatic Diseases
Search or Browse by Day

Pharmaco-Economics of Treatments for Rheumatic Diseases

CRC26
Cost-Utility Analysis of a Rheumatologist’s Treatment of Osteoarthritis of the Knee Supports the Usage of Hyaluronic Acid (Euflexxa™)
CRC27
Impact of Co-Morbidity Burden on Real World Health Care Costs of Rheumatoid Arthritis Patients Initiating Anti-Tumor Necrosis Factor Therapy
CRC28
Impact of Anti-Tumor Necrosis Factors on Healthcare Costs in Patients with Rheumatoid Arthritis
CRC29
Comparison of Therapeutic Persistence Among Anti-Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis
CRC30
Assessing the Relationship between the Number of Biological Agents Ever Used and Clinical Outcomes and Work Productivity in Patients with Rheumatoid Arthritis
CRC31
Infliximab and Adalimumab in the Treatment of Patients with Rheumatoid Arthritis: Physicians and Patients Survey
CRC32
A Five-Year Longitudinal Analysis Comparing Dose Changes for Patients with Rheumatoid Arthritis Taking Infliximab in a Medicare and in a Commercially Insured Population
CRC33
Cost of Illness: Systemic Lupus Erythematosus Versus Lupus Nephritis
CRC34
The Association between Co-Existing Immune Mediated Inflammatory Diseases and the Healthcare Costs in Patients with Rheumatoid Arthritis who Received Anti-Tumor Necrosis Factors
CRC35
Infliximab Treated Rheumatoid Arthritis Patients: Physicians and Patients Survey
CRC36
Factors Predicting Work Loss and Productivity Impairment Using Worker Productivity and Impairment Questionnaire in Patients with Rheumatoid Arthritis
CRC37
Prediction Models of Rheumatoid Arthritis (RA) Disease Activity Using Macro Economic Variables, Based on Gross Domestic Product (GDP) and Total National Health Expenditure Per Capita (TNEH) in Different Countries
CRC38
The Value of Convenience: Are Patients Willing to Trade-Off Other Attributes of Treatment for Better Convenience?
CRC39
The Association between Therapeutic Persistence and Non-Pharmacy Cost Among Anti-Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis
CRC40
Stability of Dosing in Long-Term Rheumatoid Arthritis Patients Receiving Infliximab
CRC41
Switching Patterns Among Anti-Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis
CRC42
Time to Anti-Tumor Necrosis Factor Initiation from Rheumatoid Arthritis Diagnosis
CRC43
The Impact of Anti-Tumor Necrosis Factors on Healthcare Costs in Patients with Immune Mediated Inflammatory Diseases
CRC44
Cutaneous Lupus Erythematosus Patients Have Significantly Worse Quality of Life Than Healthy Normal Volunteers
CRC45
Household Income and Quality of Life in Patients with Rheumatoid Arthritis: Results from a Mestizo Population with Full Health-Care Coverage
CRC46
Comparing Medical Utilization and Expenditures Between Switchers and Non Switchers for Tumor Necrosis Factor Inhibitors (anti-TNFs) in the Treatment of Rheumatoid Arthritis
CRC47
Persistency among Anti-Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis from a Payor Perspective
CRC48
Impact of Anti-Tumor Necrosis Factors on Health Care Resource Utilization in Patients with Immune-Mediated Inflammatory Diseases
CRC49
Infliximab Dosing Patterns and Cost are Stable in the Treatment of Rheumatoid Arthritis Disease
CRC50
Comparison of Switching Patterns among Anti-Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis
See more of: CRC Abstract Submission ACR Clinical Research Conference Poster
<< Previous Session Level | Next Session Level >>